AI & Machine Learning– category –
-
Microsoft’s AI Growth Strategy Rebuilds Investor Confidence Through OpenAI Partnership and Enterprise Integration
Yahoo Finance USA Overview Microsoft's expanding AI business has reportedly rebuilt investor confidence, with its stock price rising over 20% since early 2026. This resurgence in confidence stems from its successful strategic alliance wi... -
China Enacts First-Ever AI Companion Regulations, Halting Major Services and Mandating Measures Against Emotional Over-Reliance
Just Security China Overview China's first AI companion regulations, effective July 15, 2026, forced major Chinese AI platforms to cease customized AI persona services used by millions. These rules target emotional dependency itself as a... -
China Intensifies AI Regulation in 2026 with Mandatory Algorithm Registration and Ethical Review for AI Agents
techletter by Nesibe China Overview China is tightening its AI and AI agent regulations through the Cyberspace Administration of China's (CAC) algorithm registration system. In March 2026, the Ministry of Industry and Information Technol... -
Global AI M&A Deals Approach $1 Billion in H1 2026, Significantly Outpacing Previous Year
The Economic Times India Overview AI-related M&A activity has surged in 2026, with 25 deals totaling $980 million by August 6, already exceeding the $624 million recorded for the entirety of 2025. This acceleration is driven by compa... -
AI & Machine Learning Weekly Report August 9, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 09, 2026 (PDF) — Download Weekly Report August 09, 2026 (PDF) — DownloadDownload 🎙 Podcast August 09, ... -
BlossomHill and Latigo Secure $496 Million in Combined IPOs, Fueling Clinical-Stage Cancer and Non-Opioid Pain Therapies
Endpoints News USA Overview BlossomHill Therapeutics and Latigo Biotherapeutics successfully completed their IPOs, raising a combined total of $496 million, with $150 million for BlossomHill and $346 million for Latigo. These substantial... -
Replimune’s Tudriqev Secures FDA Accelerated Approval for Advanced Melanoma After Two Prior Rejections
BioPharma Dive USA Overview Replimune has achieved FDA accelerated approval for its advanced melanoma drug, Tudriqev, following two prior rejections and eventual support from an FDA advisory committee. The drug is approved for use in com... -
After Two Rejections, Replimune’s Melanoma Drug RP1 Secures Coveted FDA Accelerated Approval for Combination Therapy
Endpoints News USA Overview Replimune has successfully obtained FDA accelerated approval for its advanced melanoma drug, RP1 (marketed as Tudriqev), following a year-long dispute and two prior rejections. The approval, based on a Phase 2... -
Private Investors Reroute $8.8 Billion into Emerging Market AI Data Centers, Reshaping Global AI Infrastructure Strategy
Briefs Finance USA Overview In the first half of 2026, private investors poured a significant $8.8 billion into AI projects in developing nations, primarily funding data centers and AI companies. Regions like India, China, Mexico, Africa... -
KKR Acquires Medtech Giant Integer Holdings for $5.7 Billion, Signaling AI’s Growing Influence on Biotech Investment
Fierce Biotech USA Overview KKR has sealed a $5.7 billion deal to take Integer Holdings, a prominent medical technology manufacturer, private. This significant M&A transaction underscores a broader trend of large-scale deals within t...
